Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 9, 2024
Daily News
April 9, 2024
- R&D Jobs Make Up 40% of Pharma New Grads Hires This Spring, Sales Reps Only 20%: Poll
April 9, 2024
- JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
April 9, 2024
- Lawmakers’ Group on Pollen Allergy to Compile Opinion Paper towards Honebuto
April 9, 2024
- Toray Nets Positive Preclinical Data in Polymer-Conjugated Cancer Drug
April 9, 2024
- Renalys Submits IND for Japan PIII Study of IgA Nephropathy Drug
April 9, 2024
- LDP Generic League to Soon Draw Up Proposal towards Honebuto Policy
April 9, 2024
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- Janssen Files Amivantamab Plus Lazertinib for NSCLC in Japan
April 9, 2024
- Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…